· PC
· PK
· PD
Structure |
· Iodine-containing · Similar appearance to thyroxine |
Presentation |
· Tablets · Aqueous solution |
Administration |
· Arrest 300mg push · IV loading 150mg 1/24 then 850mg 23/24 · PO loading 10-20mg/kg/day for 7-10 days · Maintenance: ~100-200mg daily |
Time course |
· IV onset 5 minutes · IV duration 30 mins for bolus |
Absorption |
· Variable |
Distribution |
· VD 70L/kg · Plasma protein binding >95% (can displace other highly bound drugs e.g. warfarin) · Tissue protein binding very high · Lipid solubility high |
Metabolism |
· Hepatic CYP · Cl 1.5-11mL/kg/min · t1/2β 15-140 days · Active metabolite desethylamiodarone |
Excretion |
· Bile, skin, tears |
Antiarrhythmic class |
· Broad spectrum: class 3 > 1,2,4 · ↓K+ rectifier conductance -> prolongs phase 3 of ventricular action potential |
Use |
· Ablation of supraventricular and ventricular tachyarrhythmias · Rate control in AF |
CVS toxicity |
(especially if rapid infusion) · Hypotension · Bradycardia (resistant to atropine) · ↑QTc -> ↑risk torsades de pointes |
Tissue toxicity |
· Cirrhosis · Pulmonary fibrosis · Thyroid disease (hypo > hyper) · Corneal disease |
Feedback welcome at ketaminenightmares@gmail.com